Overview

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and tolerability of multiple intravenously administered doses of PD-0360324 in patients with cutaneous lupus erythematosus. Changes in disease activity will also be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer